Chryso Kanthou

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11860157/publications.pdf

Version: 2024-02-01

37 papers	2,883 citations	304743 22 h-index	377865 34 g-index
38 all docs	38 docs citations	38 times ranked	3559 citing authors

#	Article	IF	Citations
1	The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate. Scientific Reports, 2020, 10, 9926.	3.3	7
2	Debunking the Myth of the Endogenous Antiangiogenic Vegfaxxxb Transcripts. Trends in Endocrinology and Metabolism, 2020, 31, 398-409.	7.1	5
3	Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. British Journal of Radiology, 2019, 92, 20180405.	2.2	12
4	Rational Design of Cholesterol Derivative for Improved Stability of Paclitaxel Cationic Liposomes. Pharmaceutical Research, 2018, 35, 90.	3.5	14
5	Evaluation of Sydnoneâ€Based Analogues of Combretastatin Aâ€4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy. ChemMedChem, 2018, 13, 2618-2626.	3.2	7
6	The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate. Oncotarget, 2017, 8, 95648-95661.	1.8	5
7	Topological Analysis of the Vasculature ofÂAngiopoietin-Expressing Tumours Through Scale-Space Tracing. Communications in Computer and Information Science, 2017, , 285-296.	0.5	0
8	Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4. Journal of Medicinal Chemistry, 2016, 59, 9473-9488.	6.4	44
9	Perioperative use of iloprost in cardiac surgery patients diagnosed with heparinâ€induced thrombocytopeniaâ€reactive antibodies or with true <scp>HIT</scp> (<scp>HIT</scp>â€reactive antibodies) Tj ETQq1 1 0.784314 rgBT	4.1	84
10	Tumour Cells Expressing Single VEGF Isoforms Display Distinct Growth, Survival and Migration Characteristics. PLoS ONE, 2014, 9, e104015.	2.5	14
11	Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies. International Journal of Cancer, 2013, 133, n/a-n/a.	5.1	11
12	Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale. PLoS ONE, 2012, 7, e35231.	2.5	46
13	Vascular effects dominate solid tumor response to treatment with combretastatin Aâ€4â€phosphate. International Journal of Cancer, 2011, 129, 1979-1989.	5.1	32
14	Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. International Journal of Experimental Pathology, 2009, 90, 284-294.	1.3	175
15	Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoformâ€“Producing Tumors. Cancer Research, 2008, 68, 2301-2311.	0.9	92
16	Vascular Disrupting Agents in Cancer Therapy. , 2008, , 809-829.		1
17	Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton. Drug Discovery Today: Therapeutic Strategies, 2007, 4, 237-243.	0.5	6
18	Radiation Effects on the Cytoskeleton of Endothelial Cells and Endothelial Monolayer Permeability. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1553-1562.	0.8	75

#	Article	IF	Citations
19	Tumour targeting by microtubule-depolymerising vascular disrupting agents. Expert Opinion on Therapeutic Targets, 2007, 11, 1443-1457.	3.4	71
20	The endothelial cytoskeleton as a target of electroporation-based therapies. Molecular Cancer Therapeutics, 2006, 5, 3145-3152.	4.1	106
21	Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression. BMC Cancer, 2006, 6, 280.	2.6	33
22	Disrupting tumour blood vessels. Nature Reviews Cancer, 2005, 5, 423-435.	28.4	867
23	The Tubulin-Binding Agent Combretastatin A-4-Phosphate Arrests Endothelial Cells in Mitosis and Induces Mitotic Cell Death. American Journal of Pathology, 2004, 165, 1401-1411.	3.8	125
24	The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. Anticancer Research, 2003, 23, 3199-206.	1.1	13
25	The tumor vascular targeting agent combretastatin Aâ€“4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood, 2002, 99, 2060-2069.	1.4	270
26	Mechanisms of cytotoxicity induced by horseradish peroxidase/indole-3-acetic acid gene therapy. Journal of Cellular Biochemistry, 2002, 87, 221-232.	2.6	27
27	The biology of the combretastatins as tumour vascular targeting agents. International Journal of Experimental Pathology, 2002, 83, 21-38.	1.3	292
28	Expression of vascular endothelial growth factor receptors in smooth muscle cells. Journal of Cellular Physiology, 2001, 188, 359-368.	4.1	198
29	The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. Blood, 2000, 95, 2008-2014.	1.4	40
30	Cellular Effects and Signalling Pathways Activated by the Anti-Coagulant Factor, Protein S, in Vascular Cells. Advances in Experimental Medicine and Biology, 2000, 476, 155-166.	1.6	12
31	Cellular and Molecular Effects of Thrombin in the Vascular System. , 1998, , 263-282.		2
32	Induction of Vascular SMC Proliferation by Urokinase Indicates a Novel Mechanism of Action in Vasoproliferative Disorders. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2848-2854.	2.4	76
33	Involvement of Pertussis toxin-sensitive and -insensitive G proteins in Î±-thrombin signalling on cultured human vascular smooth muscle cells. Cellular Signalling, 1996, 8, 59-66.	3.6	27
34	Evidence for Cultured Human Vascular Smooth Muscle Cell Heterogeneity: Isolation of Clonal Cells and Study of their Growth Characteristics. Thrombosis and Haemostasis, 1996, 75, 854-858.	3.4	38
35	Prothrombin cleavage by human vascular smooth muscle cells: A potential alternative pathway to the coagulation cascade. Journal of Cellular Biochemistry, 1995, 59, 514-528.	2.6	8
36	Thrombin Receptor Activating Peptide (TRAP) Stimulates Mitogenesis, c-fos and PDGF-A Gene Expression in Human Vascular Smooth Muscle Cells. Thrombosis and Haemostasis, 1995, 74, 1340-1347.	3.4	25

#	Article	IF	Citations
37	Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells. FEBS Letters, 1992, 314, 143-148.	2.8	73